The highly polymorphic human glucocorticoid receptor gene (GR) encodes the transcriptionally active GR? isoform similar to murine GR, GR?, an isoform with reduced transactivation potential and GR?, a dominant-negative isoform. Studies in human non-erythroid cells have identified that the pattern of GR isoform expression predicts cellular response to DXM in vitro. In addition, GR polymorphism is emerging as the leading cause for DXM unresponsiveness or for development of DXM resistance in patients with inflammatory and autoimmune diseases and in chronic depression. Clinical observations indicating that the GR ligand dexamethasone (DXM) stimulates erythropoiesis have been available since 1961. DXM is used as erythropoiesis stimulating agent (ESA) to rescue the deficient terminal erythroid (EB) maturation observed in patients with Diamond Blackfan Anemia (DBA), a congenic form of erythropoietin (EPO) resistant erythroid aplasia often associated with mutations that result in ribosome insufficiency. However the effects of the various GR isoforms on terminal erythroid maturation and whether these effects may determine DXM unresponsiveness in DBA patients (~50% of DBA patients do not respond to DXM) is still unknown. We recently identified that the rs6198 single nucleotide polymorphism (SNP) that stabilizes GRb mRNA is present with increased frequency in diseases of terminal EB maturation, associated with overproduction and erythrocytosis, as in polycythemia vera (55%) as well as underproduction (anemia) as in DBA (43%) (Varricchio et al, Blood 2011;218;425-436 and 473-474). These observations have generated a paradigm shift in our understanding of DXM as ESA highlighting the clinical need for additional studies on the effect of GR polymorphism on terminal EB maturation. We propose to characterize the biological activity of different GR isoforms in terminal EB maturation (Aim 1), to identify the microenvironmental and genetic factor(s) that regulate expression of these GR isoforms during terminal EB maturation (Aim 2) and to investigate the role exerted by individual GR isoforms in rescuing terminal EB maturation in DBA patients in vitro (Aim 3). We predict that these studies, by improving our understanding of the biology of GR in normal and DBA erythropoiesis, may identify more potent GR agonists (Aim 1) and pharmacological modulators (microenvironmental factors, Aim 2) to improve the treatment of DBA patients and possibly of other EPO resistant anemias.

Public Health Relevance

The glucocorticoid receptor (GR) interacts with EPO-R signaling in switching terminal erythroid maturation from a steady-state to a stress mode. By understanding the role of individual GR isoforms in the induction of this switch, this proposal may greatly improve our understanding of the pathobiology of EPO resistant anemias, such as DBA, and contribute to the identification of alternative erythroid stimulating agents for their treatment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL116329-01
Application #
8416617
Study Section
Special Emphasis Panel (ZHL1-CSR-O (S1))
Program Officer
Thomas, John
Project Start
2012-09-26
Project End
2016-06-30
Budget Start
2012-09-26
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$423,750
Indirect Cost
$173,750
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2017) The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp Hematol 50:53-76
Klionsky, Daniel J (see original citation for additional authors) (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222
Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12
Engert, Andreas; Balduini, Carlo; Brand, Anneke et al. (2016) The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica 101:115-208
Ceglia, Ilaria; Dueck, Amylou C; Masiello, Francesca et al. (2016) Preclinical rationale for TGF-? inhibition as a therapeutic target for the treatment of myelofibrosis. Exp Hematol 44:1138-1155.e4
Spitalnik, Steven L; Triulzi, Darrell; Devine, Dana V et al. (2015) 2015 proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium. Transfusion 55:2282-90
Funnell, Alister P W; Prontera, Paolo; Ottaviani, Valentina et al. (2015) 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood 126:89-93
Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2015) Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. Haematologica 100:178-87
Heideveld, Esther; Masiello, Francesca; Marra, Manuela et al. (2015) CD14+ cells from peripheral blood positively regulate hematopoietic stem and progenitor cell survival resulting in increased erythroid yield. Haematologica 100:1396-406
Ciaffoni, Fiorella; Cassella, Elena; Varricchio, Lilian et al. (2015) Activation of non-canonical TGF-?1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells Mol Dis 54:234-41

Showing the most recent 10 out of 25 publications